Page 13 - Bharat Biotech

Study on Covishield, Covaxin antibody response is limited: Bharat Biotech

Raches Ella, project lead, Covid-19 vaccines at the firm says he is surprised that media and researchers are drawing conclusions based on non-peer reviewed work

Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals

The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

Free Covid-19 vaccine for all above 18 years from June 21: PM Modi

Of the total vaccine availability, 75 per cent will be procured by the Centre and the remaining 25 per cent will continue to be available for private hospitals.

Covishield shows better antibody response than Covaxin, says study

The study was aimed at analysing the antibody response after two complete doses of Covishield and Covaxin in Indians

Do not politicise GST Council: Finance Minister Nirmala Sitharaman

The government is conscious of the intensity of the second wave of Covid-19 and is assessing its full impact before coming out with further packages and interventions, says FM Sitharaman

Bharat Biotech, Ocugen extend agreement to market Covaxin in Canada

Phase 3 analysis data to be submitted to WHO soon for EUL

Decoded: Who can get antibody cocktail for Covid-19 and how it works

Used to treat only mild to moderate disease in high-risk Covid-19 patients, doctors feel the treatment can bolster the fight against severe disease

Bharat Biotech to ramp up production of Covaxin to 100-120 mn doses by July

There has been shortage of vaccines after it was decided to open up vaccination to all those above 18 years.

World should learn the right lessons from India's Covid-19 cataclysm

All nations should now understand that vaccines work and that interfering with their supply is dangerous.

Production of Covaxin is a complex, time-consuming process: Bharat Biotech

Bharat Biotech on Friday said production and supply of Covaxin is a time-consuming process as various procedures and approvals need to be in place before it is made available for vaccination.

Shortage of transparency

Govt, companies must end opacity on vaccine supplies

Bharat Biotech gives request to Brazilian regulator for Covaxin approval

Earlier, Anvisa denied permission to import Covaxin after its authorities found that the plant in which the jab is being made did not meet the Good Manufacturing Practice (GMP) requirements

ICMR to examine effectiveness of SII's Covishield, Bharat Biotech's Covaxin

The Indian Council of Medical Research (ICMR) will conduct a survey from next week to examine the effectiveness of these vaccines in preventing progression of COVID into a severe form.

India a dysfunctional anarchy?

It is the people who lost as the government scored self-goals

Bharat Biotech expects EUL from WHO for Covaxin by Jul-Sept period

Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, according to WHO guidelines

WHO nod for Covaxin expected in July-September period: Bharat Biotech

Company says regulatory approvals for Covaxin are also in process in more than 60 countries, including the US, Brazil, Hungary

Delhi yet to receive more Covid-19 vaccines for 18-44 group, says Atishi

Delhi is yet to receive more vaccines for the 18-44 age group and only private hospitals are giving jabs to beneficiaries in this category for now, Aam Aadmi Party MLA Atishi said on Tuesday

Bharat Biotech's US partner Ocugen submits 'Master File' to FDA on Covaxin

Ocugen, Bharat Biotech's American partner for Covaxin, has submitted a 'Master File' to the US Food and Drug Administration prior to seeking an emergency use authorisation in that country

WHO seeks more details from Bharat Bio for emergency use listing of Covaxin

The World Health Organisation (WHO) said more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its Covaxin vaccine for COVID-19. The latest Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process' guidance document dated May 18 on the WHO website said Bharat Biotech submitted EOI (Expression of Interest) on April 19 and that More information required. A pre-submission meeting is expected to be planned May-June 2021, the guidance document said. According to the WHO, submissions to it for prequalification or listing under the emergency use procedure are confidential. If a product submitted for assessment is found to meet the criteria for listing, WHO will publish the results widely. Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency. Meanwhile, Bharat Biotech International Limited (BBIL) has conveyed